Your browser doesn't support javascript.
loading
Therapeutic Management and Long-Term Outcome of Hyperthyroidism in Patients with Antithyroid-Induced Agranulocytosis: A Retrospective, Multicenter Study.
García Gómez, Carlos; Navarro, Elena; Alcázar, Victoria; López-Guzmán, Antonio; Arrieta, Francisco; Anda, Emma; Biagetti, Betina; Guerrero-Pérez, Fernando; Villabona, Carles; de Assín Valverde, Andrés Ruiz; Lamas, Cristina; Lecumberri, Beatriz; Rosado Sierra, José Antonio; Sastre, Julia; Díez, Juan José; Iglesias, Pedro.
Afiliación
  • García Gómez C; Department of Endocrinology and Nutrition, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), 28222 Madrid, Spain.
  • Navarro E; Department of Medicine, Universidad Autónoma de Madrid, 28046 Madrid, Spain.
  • Alcázar V; Department of Endocrinology and Nutrition, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
  • López-Guzmán A; Department of Endocrinology and Nutrition, Hospital Universitario Severo Ochoa, 28914 Madrid, Spain.
  • Arrieta F; Department of Endocrinology and Nutrition, Complejo Asistencial de Ávila, 05004 Ávila, Spain.
  • Anda E; Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
  • Biagetti B; Department of Endocrinology and Nutrition, Complejo Hospitalario de Navarra, 31008 Pamplona, Spain.
  • Guerrero-Pérez F; Department of Endocrinology and Nutrition, Hospital Universitari Vall d'Hebrón, 08035 Barcelona, Spain.
  • Villabona C; Department of Endocrinology and Nutrition, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • de Assín Valverde AR; Department of Endocrinology and Nutrition, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Lamas C; Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain.
  • Lecumberri B; Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain.
  • Rosado Sierra JA; Department of Endocrinology and Nutrition, Hospital Universitario La Paz, 28046 Madrid, Spain.
  • Sastre J; Department of Endocrinology and Nutrition, Hospital Universitario Getafe, 28905 Madrid, Spain.
  • Díez JJ; Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario de Toledo, 45007 Toledo, Spain.
  • Iglesias P; Department of Endocrinology and Nutrition, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), 28222 Madrid, Spain.
J Clin Med ; 12(20)2023 Oct 16.
Article en En | MEDLINE | ID: mdl-37892693
BACKGROUND: Antithyroid drug-induced agranulocytosis (AIA) (neutrophils <500/µL) is a rare but serious complication in the treatment of hyperthyroidism. METHODOLOGY: Adult patients with AIA who were followed up at 12 hospitals in Spain were retrospectively studied. A total of 29 patients were studied. The etiology of hyperthyroidism was distributed as follows: Graves' disease (n = 21), amiodarone-induced thyrotoxicosis (n = 7), and hyperfunctioning multinodular goiter (n = 1). Twenty-one patients were treated with methimazole, as well as six patients with carbimazole and two patients with propylthiouracil. RESULTS: The median (IQR) time to development of agranulocytosis was 6.0 (4.0-11.5) weeks. The most common presenting sign was fever accompanied by odynophagia. All of the patients required admission, reverse isolation, and broad-spectrum antibiotics; moreover, G-CSF was administered to 26 patients (89.7%). Twenty-one patients received definitive treatment, thirteen patients received surgery, nine patients received radioiodine, and one of the patients required both treatments. Spontaneous normalization of thyroid hormone values occurred in six patients (four patients with amiodarone-induced thyrotoxicosis and two patients with Graves' disease), and two patients died of septic shock secondary to AIA. CONCLUSIONS: AIA is a potentially lethal complication that usually appears around 6 weeks after the initiation of antithyroid therapy. Multiple drugs are required to control hyperthyroidism before definitive treatment; additionally, in a significant percentage of patients (mainly in those treated with amiodarone), hyperthyroidism resolved spontaneously.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza